Cooperative Agreement UG3DA063211
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $749K
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
New York, NY 10029, USA
Similar Awards
- The National Institute on Drug Abuse awarded Icahn School of Medicine at Mount Sinai $796,299 on September 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct single chromatin fiber multiomic mapping in opioid use disorder brain tissue. The recipient will perform genome-wide profiling of chromatin organization directly from frontal and cingulate cortex nuclei obtained from donors with chronic opioid use disorder. The work charts nucleosomal array organization,...
- The National Institute on Drug Abuse awarded Icahn School of Medicine at Mount Sinai $100,228 on October 8, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support research on opioid reward mechanisms. The award funds a project investigating the functional role of a novel cortical circuit connecting the dorsal peduncular nucleus to the ventral tegmental area in mediating opioid reward. The research employs barcoded anatomy resolved by sequencing combined with spatial...
- The National Institute on Drug Abuse awarded a $2.690732 million cooperative agreement to Lovelace Biomedical Research Institute on September 30, 2025, to support research applying transcranial alternating current stimulation (TACS) as an adjunct to motivational interviewing for substance use disorder treatment. The award is made under the Drug Use and Addiction Research Programs (CFDA 93.279), which supports research on prevention, diagnosis, and treatment of drug use, misuse, and addiction....
- The National Institute on Drug Abuse awarded Research Foundation For Mental Hygiene, Inc. (operating as New York State Psychiatric Institute) $450,175 on May 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279). The award funds a clinical trial testing sphenopalatine ganglion (SPG) blocks as an adjunctive treatment to buprenorphine for individuals with opioid use disorder who test positive for high-potency synthetic opioids. The study will enroll 40 participants, all...
- The National Institute on Drug Abuse awarded Icahn School of Medicine at Mount Sinai $720,691 on August 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to design and develop blood-brain barrier-crossing conjugates that enable delivery of antisense oligonucleotides to the brain for treating cocaine use disorder. The project addresses the lack of FDA-approved medications for cocaine use disorder by leveraging recent advances in antisense oligonucleotide technologies to...
- The National Institute on Drug Abuse awarded Icahn School of Medicine at Mount Sinai $2.35 million on February 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to mine transcriptomic datasets and resolve functionally relevant striatal cell types in response to HIV infection and opioid use. The recipient will analyze single-nucleus RNA sequencing, two-dimensional single-cell spatial transcriptomic, and three-dimensional single-cell spatial transcriptomic data generated...
- The National Institute on Drug Abuse awarded Icahn School of Medicine at Mount Sinai $181,092 on May 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate dopamine receptor type 2 (D2)-expressing cells in the ventral hippocampus and their role in cocaine relapse vulnerability. The research comprises three aims conducted in New York, NY through April 30, 2028. Aim 1 characterizes ventral hippocampus D2 neuron activity during cocaine intravenous...
- The National Institute on Drug Abuse awarded The Research Foundation For The State University Of New York (operating as Stony Brook University) $716,669 on June 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a longitudinal study examining metacognitive circuit impairments in opioid use disorder and their associations with illicit drug use and quality of life. The research confirms metacognitive underconfidence in opioid-dependent participants maintained on...
- The National Institute on Drug Abuse awarded Icahn School of Medicine at Mount Sinai $2.352 million on February 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct single-molecule functional validation of neurogenomic alterations in opioid-exposed HIV brain tissue. The project performs single-molecule fiber-seq profiling on cingulate cortex tissue samples from the SCORCH (Single Cell Opioid Response in the Context of HIV) consortium, analyzing approximately...
- The National Institute on Drug Abuse, a component of the Department of Health and Human Services, awarded Albert Einstein College of Medicine $252,000 under the Drug Use and Addiction Research Programs (CFDA 93.279) on May 1, 2026. The award funds a 12-week pilot randomized controlled trial (DEMURE Trial) evaluating dronabinol (synthetic THC) and epidiolex (cannabidiol) as adjunctive treatments to buprenorphine for persons with opioid use disorder experiencing protracted withdrawal symptoms...